

## Movin' On Up!

This month marks an important development for *JNCCN*. Historically, the journal was organized around the NCCN Guidelines, and it made sense that the NCCN Guidelines Panel Chairs would serve as the only Editorial Board. The NCCN Guidelines will always be an important part of *JNCCN*, but a few years ago, we started to shape the journal differently. In addition to providing the NCCN Guidelines, we aimed to also make it a home for research in health services, outcomes, comparative effectiveness, and quality improvement, with a nice counterbalance in clinical science provided by our feature titled “Molecular Insights in Patient Care.” Even if I do say so myself, I think we were pretty successful. Our submissions for original research have increased nearly 5-fold, our page views have doubled, the impact factor has risen nearly a full point, and, as of writing, we are the 4th ranked oncology journal for average issue readers in a national independent readership survey.<sup>1</sup>

For all these reasons, we felt it was important to select new Associate Editors to handle this upward trajectory. After an extensive national search among NCCN Member Institutions, we have selected a very talented group of experts to assist in the editorial process. This issue represents their debut. I'm proud to welcome the following Associate Editors to our team: Sara H. Javid, MD, University of Washington/Seattle Cancer Care Alliance; Ticiana A. Leal, MD, University of Wisconsin Carbone Cancer Center; June M. McKoy, MD, MPH, JD, MBA, Robert H. Lurie Comprehensive Cancer Center of Northwestern University; Anthony J. Olszanski, MD, RPh, Fox Chase Cancer Center; Oxana Palesh, PhD, MPH, Stanford Cancer Institute; Jeffrey Peppercorn, MD, MPH, Harvard Medical School/Massachusetts General Hospital Cancer Center; Kanishka Sircar, MD, The University of Texas MD Anderson Cancer Center; and Grace L. Smith, MD, PhD, MPH, The University of Texas MD Anderson Cancer Center.

Of course, I would be remiss not to extend a heartfelt thank you to my former Executive Editorial Board, composed of a subset of NCCN Guidelines Panel Chairs. They have guided me through many decisions and provided invaluable advice over the past few years. Please join me in thanking Al B. Benson III, MD, Robert H. Lurie Comprehensive Cancer Center of Northwestern University; Mary B. Daly, MD, PhD, Fox Chase Cancer Center; Crystal S. Denlinger, MD, Fox Chase Cancer Center; and Andrew D. Zeleznitz, MD, PhD, Memorial Sloan Kettering Cancer Center; and previous members Robert J. Morgan, MD, City of Hope Comprehensive Cancer Center, and the late Jimmie C. Holland, Memorial Sloan Kettering Cancer Center.

Finally, don't think that the NCCN Guidelines Panel Chairs are off the hook. They remain with us as the NCCN Guidelines Editorial Board and are pressed into service often to suggest topics or weigh-in on editorial decisions involving any aspect of the guidelines.

I'm pretty excited about these changes. They represent a really important step for the journal, and I know this new Board will help *JNCCN* become even more successful and competitive. Just like the theme song from *The Jeffersons* sitcom says, “We're movin' on up!”

## Reference

1. December 2017 Medical/Surgical Readership study, table 127. New York, NY: Kantar Media.



### Margaret Tempero, MD

Margaret Tempero, MD, is a Professor of Medicine and Director of the UCSF Pancreas Center and editor-in-chief of *JNCCN*. Her research career has focused on pancreatic ductal adenocarcinoma, especially in the area of investigational therapeutics. Dr. Tempero has served on the ASCO Board of Directors and as ASCO President. She currently serves on the ASCO Conquer Cancer Foundation Board. She codirected the AACR/ASCO Methods in Clinical Cancer Research and taught this course and similar courses in Europe and Australia. She was founding Chair of the NCI Clinical Oncology Study Section and served as a member and Chair of the NCI Board of Scientific Counselors Subcommittee A. She is a member of the Scientific Steering Committee and Chair of the Clinical and Translational Study Section for the Cancer Prevention & Research Institute of Texas. She is or has been on the Scientific Advisory Boards of the Lustgarten Foundation, the Pancreatic Cancer Action Network, the V Foundation, The Alberta Canada Cancer Board, and the EORTC. She served as a member of the Oncology Drug Advisory Committee for the FDA. She has served as Deputy Director and Interim Director for the UNMC Eppley Cancer Center. She is Chief Emeritus of the Division of Medical Oncology at UCSF and served as the founding Deputy Director and Director of Research Programs at the UCSF Helen Diller Family Comprehensive Cancer Center.

doi: 10.6004/jnccn.2018.0057

The ideas and viewpoints expressed in this editorial are those of the author and do not necessarily represent any policy, position, or program of NCCN.

**What do you think?** Please e-mail correspondence (include contact information) to [JNCCN@nccn.org](mailto:JNCCN@nccn.org) or log into [www.editorialmanager.com/JNCCN](http://www.editorialmanager.com/JNCCN) to submit a Letter to the Editor.